Andres Poveda, MD, on the Phase III SOLO2/ENGOT-ov21 Final OS Data in Ovarian Cancer

Final overall survival results from the trial showed that maintenance olaparib provided an unprecedented improvement in median overall survival versus placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

Source: CancerNetwork - June 4, 2020 Category: Cancer & Oncology Authors: Andres Poveda, MD Source Type: news